Literature DB >> 24474837

Prothrombin complex concentrate.

Dennis J Cada1, Terri L Levien2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The December 2013 monograph topics are vortioxetine, mechlorethamine gel, brimonidine tartrate topical gel, obinutuzumab, and miltefosine. The DUE/MUE is on vortioxetine.

Entities:  

Year:  2013        PMID： 24474837      PMCID： PMC3875114          DOI： 10.1310/hpj4811-951

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  16 in total

Review 1.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter?

Authors:  Stacy A Voils; Brian Baird
Journal:  Thromb Res       Date:  2012-11-06       Impact factor: 3.944

Review 4.  Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Authors:  Scott Kaatz; Peter A Kouides; David A Garcia; Alex C Spyropolous; Mark Crowther; Jim D Douketis; Anthony K C Chan; Andra James; Stephan Moll; Thomas L Ortel; Elizabeth M Van Cott; Jack Ansell
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

5.  Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.

Authors:  M D Lambourne; L J Eltringham-Smith; S Gataiance; D M Arnold; M A Crowther; W P Sheffield
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

6.  Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.

Authors:  I Pragst; S H Zeitler; B Doerr; F J Kaspereit; E Herzog; G Dickneite; J van Ryn
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

7.  Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding.

Authors:  G Evans; R Luddington; T Baglin
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

8.  Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients.

Authors:  F E Preston; S T Laidlaw; B Sampson; S Kitchen
Journal:  Br J Haematol       Date:  2002-03       Impact factor: 6.998

9.  ISMP Medication Error Report Analysis.

Authors: 
Journal:  Hosp Pharm       Date:  2013-12

10.  In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.

Authors:  J Dinkelaar; P J Molenaar; M Ninivaggi; B de Laat; H J M Brinkman; A Leyte
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824
View more
  1 in total

1.  Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.

Authors:  Denise H Rhoney; Mary La; Molly Merz; Aaron Cook; Kent A Owusu; Christina Roels; Joe Blunck; Justin Shewmaker; Kiranpal S Sangha; Salia Farrokh; John Lewin; Kathleen W Chester; Theresea Human; Kathleen Bledsoe; Kristy Greene; Melissa Levesque; Jody C Rocker; Gary Davis; Ron Neyens; Timothy F Lassiter; Sarah M Adriance
Journal:  Neurocrit Care       Date:  2020-11-20       Impact factor: 3.210
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.